Seneca Biopharma Inc fka SNCA

[Seel]

Yes - there is a group of people who attack ph2 trial results as though they should all be constructed like ph3 and show clear efficacy. They went to work on this one - with nonsensical 'subset analysis' complaints. The response shown by some of these trial participants was amazing. The apparent increased decline rate of others a serious concern. Mixed results. Because of the possibility of increased rapidity of decline in nonresponders - CUR cannot yet claim safety goals met. They have to prove no increased harm to nonresponders in future trials. They can't do that without much increased confidence in identification of responder characteristics. They're in a tough and complicated but (imo) not impossible spot.